AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to ...

The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a ...

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and ...

AstraZeneca said the “cornerstone” of the commitment would be a new weight management production facility for its oral GLP-1 ...

With the threat of tariffs looming for medicines imported to the United States, AstraZeneca has unveiled a plan to invest $50 ...

AstraZeneca said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing ...